Quantumzyme Research Demonstrates Computational Enzyme Engineering Approach for Sustainable Pharmaceutical Manufacturing

Quantumzyme Corp. announced the publication of its latest research in the Journal of Molecular Graphics & Modelling, describing the company's application of a fully in silico enzyme engineering approach to support biocatalyst design and evaluation prior to laboratory validation. The peer-reviewed study examines whether enzyme variants can be computationally optimized before experimental testing, applying virtual screening and computational modeling techniques to evaluate transaminase enzyme variants used in the asymmetric synthesis of L-HPE, a chiral intermediate relevant to certain ACE inhibitor drug manufacturing processes.

Rather than relying exclusively on traditional experimental iteration, the research employed large-scale virtual screening and ranking methodologies to assess enzyme–substrate interactions, catalytic alignment, and structural stability under defined simulation conditions. This approach enabled the identification of enzyme candidates for subsequent experimental consideration, potentially improving research efficiency and better informing downstream validation efforts. According to Naveen Kulkarni, Chief Executive Officer of Quantumzyme Corp., this study contributes to the growing body of evidence supporting computational enzyme engineering as a complementary tool in biocatalyst development.

The research reflects Quantumzyme's continued commitment to advancing digital methodologies in enzyme engineering, with the company focused on integrating computational modeling with experimental workflows. While further laboratory validation and scale-up studies are required, the company believes computational biocatalysis represents an important component of future sustainable pharmaceutical manufacturing strategies. The study underscores the expanding role of computational modeling in biocatalysis research, suggesting that in silico methodologies may help reduce experimental iteration and improve the prioritization of enzyme candidates for laboratory study by supporting early-stage evaluation and hypothesis testing.

The publication does not represent regulatory approval, commercial validation, or confirmation of manufacturing readiness, with additional experimental testing, optimization, and scale-up required before any potential industrial application. The full research paper is available at https://www.sciencedirect.com/science/article/pii/S1093326326000343. Separately, Quantumzyme announced that the Financial Industry Regulatory Authority has received all information necessary to complete its review of the company's previously announced corporate name change and corresponding trading symbol request, with the company anticipating that the name change and new trading symbol are expected in the coming days subject to FINRA's final approval.